Novartis Confirms Two Zolgensma Tumors Linked to Gene Integration, Igniting Safety Debate
Novartis confirmed that two patients treated with its spinal muscular atrophy (SMA) gene therapy, Zolgensma, developed tumors caused by the drug’s viral vector integrating into their DNA. While the company acknowledged nine total tumor reports since the drug’s 2019 approval, it maintains that only two cases show evidence of causal vector integration. The disclosure, which initially surfaced via social media before official channels, has prompted regulatory review and raised concerns about the adequacy of current post-market surveillance for gene therapies.
Key points
- Novartis confirmed nine tumor reports in patients treated with Zolgensma since its 2019 approval, with two cases showing evidence of vector DNA integration into patient chromosomes.
- The two confirmed cases involved tumors developing 18 to 60 months after treatment, a latency window not formally confirmed by Novartis but reported by patient advocates.
- The FDA label for Zolgensma still describes the risk of tumorigenicity as 'theoretical' and states that a causal relationship has not been established, despite the new pathological confirmations.
- Regulatory authorities are actively reviewing the cases, while SMA advocacy groups have criticized Novartis for a 'tiered rollout' of information that prioritized specialists over public transparency.
- Novartis is simultaneously managing safety concerns for its CAR T therapy, rap-cel, following three patient deaths from immune-related complications earlier this year.
Background
Zolgensma, approved in 2019, was the first gene therapy for a heritable disease in children. Previous safety scrutiny focused on liver-related adverse events, leading to a boxed warning for acute liver failure. This latest development marks the first confirmed case of insertional mutagenesis in a commercially approved gene therapy, challenging the field's reliance on AAV vectors as a safer alternative to retroviral vectors.
How outlets are covering it
BioSpace and Tech Times agree on the core facts: Novartis confirmed nine tumor reports, with two showing vector integration. However, they differ in emphasis. BioSpace highlights the social media origin of the disclosure and the 'tiered rollout' criticism, while Tech Times focuses on the scientific mechanism of insertional mutagenesis and the gap between the FDA label and confirmed cases. Tech Times also notes that Novartis shares fell on the news, a detail not mentioned by BioSpace. Both sources acknowledge that regulatory authorities are reviewing the cases, but Tech Times provides more detail on the FDA's potential regulatory tools, such as label updates or REMS requirements.
Why it matters
This case sets a precedent for post-market surveillance of gene therapies. If the FDA mandates new surveillance requirements or label updates, it could impact the approval and monitoring of other AAV-based therapies in development. For families of the 6,000+ patients treated with Zolgensma, it raises questions about the need for active tumor surveillance in the 18-to-60-month post-treatment window.
What to watch
Regulatory authorities are expected to determine next steps, which may include label updates, mandated surveillance programs, or post-approval studies. Novartis has not indicated it will withdraw or restrict access to Zolgensma. SMA advocacy groups are likely to continue pushing for transparent communication and clear guidance for families.
Want the full story? Read the original reporting
Read on BioSpace